PUBLISHER: IMARC | PRODUCT CODE: 1468354
PUBLISHER: IMARC | PRODUCT CODE: 1468354
Gastric Cancer Drugs Market Report by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2024-2032
The global gastric cancer drugs market size reached US$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 11.26% during 2024-2032. The rising prevalence of chronic and acute indications, growing incidences of weight-related health concerns, and increasing health consciousness represent some of the key factors driving the market.
Gastric cancer drugs are medications developed to relieve or treat an individual diagnosed with stomach cancer in which malignant cells form in the lining of the stomach. Some common symptoms of gastric cancer are unexplained weight loss, indigestion, bloating, nausea, vomiting, heartburn, and difficulty swallowing food. Doxorubicin hydrochloride, sunitinib, mitomycin, fluorouracil, imatinib, and docetaxel are commonly available gastric cancer drugs. They help to shrink a tumor and relieve signs and symptoms of cancer by killing some of the cancer cells. They also assist in reducing cancer cells from growing, dividing, and making more cells. As a result, gastric cancer drugs are administered through oral and parenteral forms and are used by hospitals, clinics, and special treatment centers.
The increasing geriatric population and the rising prevalence of obesity across the globe are primarily driving the market growth. In line with this, the growing incidences of weight-related health concerns due to unhealthy eating habits and sedentary lifestyles are favoring the market growth. Moreover, the increasing cases of cancer, due to the rising consumption of tobacco-based products and alcoholic beverages, and the enhanced need need for preventive and therapeutic medications are acting as another growth-inducing factor. Apart from this, the introduction of two gastric cancer biomarkers that help in eliminating tumor growth is providing an impetus to the market growth. Moreover, manufacturers are focusing on creating product variants with minimal side effects, such as gastric erosion and nausea, thus propelling the market toward growth. Along with this, rapid technological advancements focusing on the development of effective and specific cancer treatments are creating a positive outlook for the market. Furthermore, leading pharmaceutical companies and key players are investing heavily in research and development (R&D) activities to develop gastric cancer drugs that are safer, more effective, economically viable, and easier to administer. Besides this, the implementation of various government initiatives to promote the manufacturing, processing, and packing of a drug product ensuring the quality of drugs produced by manufacturers is positively influencing the market growth. Other factors, including rising healthcare expenditure and growing consumer awareness regarding the symptoms and the available treatment options for gastric cancer, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global gastric cancer drugs market, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, route of administration, and end user.
Type Insights
Doxorubicin Hydrochloride
Sunitinib
Docetaxel
Mitomycin
Fluorouracil
Imatinib
Trastuzumab
The report has provided a detailed breakup and analysis of the gastric cancer drugs market based on the type. This includes doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. According to the report, trastuzumab represented the largest segment.
Route of Administration Insights
Oral
Parenteral
A detailed breakup and analysis of the gastric cancer drugs market based on the route of administration has also been provided in the report. This includes oral and parenteral. According to the report, parenteral accounted for the largest market share.
End User Insights
Hospitals
Clinics
Others
The report has also provided a detailed breakup and analysis of the gastric cancer drugs market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment.
Regional Insights
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, Asia Pacific was the largest market for gastric cancer drugs. Some of the factors driving the Asia Pacific gastric cancer drugs market included its high healthcare expenditure, technological advancements, and rising geriatric population.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global gastric cancer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Arog Pharamaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global gastric cancer drugs market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global gastric cancer drugs market?
- What are the key regional markets?
- Which countries represent the most attractive gastric cancer drugs market?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on end user?
- What is the competitive structure of the global gastric cancer drugs market?
- Who are the key players/companies in the global gastric cancer drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Gastric Cancer Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Doxorubicin Hydrochloride
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Sunitinib
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Docetaxel
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Mitomycin
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Fluorouracil
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Imatinib
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Trastuzumab
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Parenteral
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Arog Pharamaceuticals Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Bristol-Myers Squibb Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Daiichi Sankyo Company Limited
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Eli Lilly and company
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche AG
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Ono Pharmaceutical Co. Ltd.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Sanofi S.A.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 SWOT Analysis
- 14.3.1 Abbott Laboratories
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report
List of Figures
- Figure 1: Global: Gastric Cancer Drugs Market: Major Drivers and Challenges
- Figure 2: Global: Gastric Cancer Drugs Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Gastric Cancer Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Gastric Cancer Drugs Market: Breakup by Type (in %), 2023
- Figure 5: Global: Gastric Cancer Drugs Market: Breakup by Route of Administration (in %), 2023
- Figure 6: Global: Gastric Cancer Drugs Market: Breakup by End User (in %), 2023
- Figure 7: Global: Gastric Cancer Drugs Market: Breakup by Region (in %), 2023
- Figure 8: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 9: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 10: Global: Gastric Cancer Drugs (Sunitinib) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 11: Global: Gastric Cancer Drugs (Sunitinib) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 12: Global: Gastric Cancer Drugs (Docetaxel) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 13: Global: Gastric Cancer Drugs (Docetaxel) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 14: Global: Gastric Cancer Drugs (Mitomycin) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 15: Global: Gastric Cancer Drugs (Mitomycin) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 16: Global: Gastric Cancer Drugs (Fluorouracil) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 17: Global: Gastric Cancer Drugs (Fluorouracil) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 18: Global: Gastric Cancer Drugs (Imatinib) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 19: Global: Gastric Cancer Drugs (Imatinib) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 20: Global: Gastric Cancer Drugs (Trastuzumab) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 21: Global: Gastric Cancer Drugs (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 22: Global: Gastric Cancer Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 23: Global: Gastric Cancer Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 24: Global: Gastric Cancer Drugs (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 25: Global: Gastric Cancer Drugs (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 26: Global: Gastric Cancer Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 27: Global: Gastric Cancer Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 28: Global: Gastric Cancer Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 29: Global: Gastric Cancer Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 30: Global: Gastric Cancer Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 31: Global: Gastric Cancer Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 32: North America: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 33: North America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 34: United States: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 35: United States: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 36: Canada: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 37: Canada: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 38: Asia-Pacific: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 39: Asia-Pacific: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 40: China: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 41: China: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 42: Japan: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 43: Japan: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 44: India: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 45: India: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 46: South Korea: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 47: South Korea: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 48: Australia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 49: Australia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 50: Indonesia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 51: Indonesia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 52: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 53: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 54: Europe: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 55: Europe: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 56: Germany: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 57: Germany: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 58: France: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 59: France: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 60: United Kingdom: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 61: United Kingdom: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 62: Italy: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 63: Italy: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 64: Spain: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 65: Spain: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 66: Russia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 67: Russia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 68: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 69: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 70: Latin America: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 71: Latin America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 72: Brazil: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 73: Brazil: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 74: Mexico: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 75: Mexico: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 76: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 77: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 78: Middle East and Africa: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 79: Middle East and Africa: Gastric Cancer Drugs Market: Breakup by Country (in %), 2023
- Figure 80: Middle East and Africa: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 81: Global: Gastric Cancer Drugs Industry: Drivers, Restraints, and Opportunities
- Figure 82: Global: Gastric Cancer Drugs Industry: Value Chain Analysis
- Figure 83: Global: Gastric Cancer Drugs Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Gastric Cancer Drugs Market: Key Industry Highlights, 2023 & 2032
- Table 2: Global: Gastric Cancer Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
- Table 3: Global: Gastric Cancer Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
- Table 4: Global: Gastric Cancer Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
- Table 5: Global: Gastric Cancer Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 6: Global: Gastric Cancer Drugs Market: Competitive Structure
- Table 7: Global: Gastric Cancer Drugs Market: Key Players
